8-K: Turnstone Biologics Corp. Notified of Nasdaq Listing Transfer and Granted Extension to Regain Compliance

Turnstone Biologics Corp. receives approval to transfer its listing to the Nasdaq Capital Market and gains an extension to meet minimum bid price requirements.

Summary

• Turnstone Biologics Corp. received notification from Nasdaq on September 27, 2024, that it did not meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days.
• The company was initially given until March 26, 2025, to regain compliance.
• On March 24, 2025, Turnstone applied to transfer its listing to the Nasdaq Capital Market.
• On March 27, 2025, Nasdaq approved the transfer, effective at the opening of business on March 31, 2025.
• The company has been granted an additional 180-day grace period, until September 22, 2025, to regain compliance with the minimum bid price requirement.
• To regain compliance, the stock price must be at least $1.00 for at least ten consecutive business days.
• The company plans to implement a reverse stock split to achieve this, subject to stockholder approval.
• If compliance is not achieved by September 22, 2025, the company's stock may be delisted.
• Turnstone may appeal a delisting decision to a Nasdaq Hearings Panel, during which time the stock would remain listed.
• If delisted, the stock may trade on the OTC Bulletin Board or other small trading markets.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the delisting notice and the need for a reverse stock split. However, the extension granted by Nasdaq provides some hope for recovery.

Positives

• The company received approval to transfer to the Nasdaq Capital Market.
• Turnstone has been granted an additional 180-day grace period to regain compliance with the minimum bid price requirement.
• The company has a plan to implement a reverse stock split to regain compliance.

Negatives

• The company failed to maintain the minimum bid price of $1.00 per share, leading to the delisting notice.
• Failure to regain compliance by September 22, 2025, could result in delisting from Nasdaq.

Risks

• Failure to regain compliance with the minimum bid price requirement by September 22, 2025, could lead to delisting.
• The reverse stock split is subject to stockholder approval and may not be sufficient to raise the stock price above $1.00.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement by implementing a reverse stock split and achieving a stock price of at least $1.00 for ten consecutive business days by September 22, 2025.

Management Comments

• Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer and Director, signed the report on behalf of Turnstone Biologics Corp.

Industry Context

Many biotech companies, especially those in the development stage, can face challenges in maintaining share price compliance, particularly in volatile market conditions. Transferring to the Nasdaq Capital Market provides some relief with less stringent requirements, but the underlying business and investor confidence remain critical.

Comparison to Industry Standards

• Many small-cap biotech companies face similar listing challenges, often resorting to reverse stock splits to maintain compliance.
• Companies like XOMA Corporation have previously used reverse stock splits to regain compliance with Nasdaq listing requirements.
• The success of Turnstone's strategy will depend on its ability to demonstrate progress in its clinical programs and maintain investor confidence.

Stakeholder Impact

• Shareholders face the risk of further stock dilution if the reverse stock split is implemented.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's ability to raise capital and fund its research programs could be affected.

Next Steps

• The company will seek stockholder approval for a reverse stock split.
• Turnstone must achieve a stock price of at least $1.00 for ten consecutive business days by September 22, 2025.
• The company may appeal a delisting decision to a Nasdaq Hearings Panel if it fails to regain compliance.

Key Dates

Keywords

Nasdaq Capital Market, minimum bid price, reverse stock split, delisting, compliance, Turnstone Biologics, TSBX